NCT01179529View on ClinicalTrials.gov

Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Atopic DermatitisAtopic Eczema
Interventions
DRUG

Omalizumab (Xolair®)

Trial Locations (1)

80802

Klinikum rechts der Isar Dermatologie/Biederstein, Munich

All Listed Sponsors
lead

Technical University of Munich

OTHER

NCT01179529 - Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage | Biotech Hunter | Biotech Hunter